medigraphic.com
Colegio de Medicina Interna de México.

2011, Number 6

<< Back Next >>

Med Int Mex 2011; 27 (6)

Clinical practice guide evidence-based for the diagnosis and treatment of osteoarthrosis

Cajigas MJC, Ariza AR, Espinosa MR, Méndez MC, Mirassou OM, Robles SRM, Santillán BE, Trillo AGI, Ventura RL, Waiss SS, Bello AE, Aldrete VJ, Cantú RAT

Language: Spanish
References: 88
Page: 552-572
PDF size: 358.20 Kb.


ABSTRACT

Background: Osteoarthritis (OA) is the most frequently rheumatic disorder seen in clinical practice. Typical sites of inflammatory involvement include hands, knees, and hips. OA diagnosis is based on clinical and radiological findings, while OA therapy consists in drug treatment and support with physical therapy, orthotic devices, and if necessary surgical intervention followed by rehabilitation and pharmacological treatment. Identification of patients with OA remains a challenge. The disparity of diagnostic and therapeutic criteria may delay the initiation of the proper treatment. It is therefore, desirable to unify the existing information and to provide physicians a practical, effective and current guideline derived from evidence-based information in order to guide their management of OA.
Methods: Ten physicians and one physiotherapist with expertise in rheumatic diseases were invited to participate in the development of the guideline based on criteria such as experience, knowledge and clinical judgment.
Results: The discussion panels were set up with expert participants who discussed the topics included in these guidelines according to their evidence and recommendation levels.
Conclusions: OA is the most frequently rheumatic disorder seen in clinical practice. It is a major cause of disability in older people, and generates serious health related detriment and social and economic negative impact. Therefore, it is imperative to create a set of clinical practice guidelines that would offer plans for an integral management of OA, in order to optimize resources and eventually improve patients quality of life.


REFERENCES

  1. CONAPO; Centro Nacional de Excelencia Tecnológica en la Salud 2008.

  2. Ehrlich EG. The rise of osteoarthritis. Bull World Health Organ 2003; 81(9): 630.

  3. Mandell BF, Collier VU, Bolster MB, et al. MKSAP14 Medical knowledge Self-Assessment Program. American College of Physicians Mex 2010:20-23.

  4. Woolf AD, Akesson K. Understanding the burden of musculoskeletal conditions. The burden is huge and not reflected in national health priorities. BMJ 2001; 322:1079-1080.

  5. Corti MC, Rigon C. Epidemiology of osteoarthritis: prevalence, risk factors and functional impact. Aging Clin Exp Res 2003 Oct;15(5):359-363.

  6. Cardiel MH, Rojas-Serrano J. Community based study to estimate prevalence, burden of iones and help seeking behavior in rheumatic diseases in Mexico City. A COPCORD study. Clin Exp Rheumatol 2002; 20:617-24.

  7. Espinosa R, Hernández L, Arroyo C. Patrón de utilización de servicios de salud en México en pacientes con artritis. Rev Mex Reumatol 2005;20:20-21.

  8. Ling SM, Bathon J. Osteoarthritis clinical presentation. Johns Hopkins Arthritis Center on Line, 2002. http://www.hopkinsarthritis.com/edu/acr/acr. html

  9. Moskowitz R. Osteoarthritis. Diagnosis and medical and surgical managment. WB Saunders 2001.

  10. Lom-Orta H. Osteoartrosis. En Introducción a la Reumatología, 4ª ed. México: Intersistemas editores, 2008; pp201-211.

  11. Amin S, Lavalley MP, Guermazi A, et al. The relationship between cartilage loss on magnetic resonance imaging and radiographic progression in men and women with knee osteoarthritis. Arthritis Rheum 2005; 52: 3152–3159.

  12. American College of Rheumatology Subcommittee on Osteoarthritis. Recommendations for the medical management of the osteoarthritis of the hip and knee. Arthritis Rheum 2002;43:1905-1915.

  13. Ministry of Health Singapore (MOH). Clinical Practice Guideline Osteoarthritis of the Knee 2007. http://www.moh.gov.sg/cpg

  14. Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for the International Clinical Studies Including Therapeutic Trials (ESCICIT). Ann Rheum Dis 2003;62:1145-1155.

  15. Towheed T, Shea B, Wells G, et al. Analgesia and non-aspirin, nonsteroidal anti-inflamatory drugs for osteoarthritis of the hip. Cochrane Database of systematic reviews. The Cochrane Library 2002; Issue 1. http://gateway/ovid.com/ovidweb.cgi

  16. McLean C. Quality indicators for the management of osteoarthritis in vulnerable elders ACOVE. Ann Intern Med 2001;135:711-721.

  17. Bjordal JM, Klovning A, Ljunggren AE, et al. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: A meta-analysis of randomized placebo-controlled trials. Eur J Pain 2007; 11: 125–138.

  18. Hyiek EM, Heiman H, Skates SJ, et al. Acetoaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998;279:657-662.

  19. García SR, Calcerrada N. Grupo de trabajo de la guía de práctica clínica del manejo del paciente con artrosis de rodilla en atención primaria. Guía de práctica clínica del manejo del paciente con artrosis de rodilla en atención primaria. Madrid: Unidad de Evaluación de Tecnologías Sanitarias (UETS), Áreas de Investigación y Estudios Sanitarios. Agencia Laín Entralgo; 2006.

  20. National Institute Clinical Excellence (NICE) Osteoarthritis National Clinical Guideline for Care and Management in adults, 2008.

  21. Little CV, Parsons T. Herbal therapy for treating osteoarthritis. Cochrane Database Syst Rev 2001;1: CD002947.

  22. Moore RA, Tramer MR, Carroll D, et al. Quantitative Systematic review of topically applied non-steroidal anti-inflammatory drugs. BMJ 1998;316:333-338.

  23. Klippel J, Stone J, et al. Primer on the Rheumatic Diseases. 13a ed. Atlanta: Arthritis Foundation, 2008; pp:634-642.

  24. Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2004;63:11-14.

  25. Espinosa R, Peña A. Osteoartritis. En Robles M, Cajigas JC, Ventura L. Reumatología para el clínico. México: Editorial Alfil, 2011; pp:305-315.

  26. Scott DL, Berry H, Capell H, et al. The long-term effects of non-steroidal anti-inflammatory drugs in osteoarthritis of the knee: a randomized placebo-controlled trial. Rheumatology (Oxford) 2000; 39(10):1095–1101.

  27. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclooxygenase- 2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006; 55: 1731–1738.

  28. Hochberg MC, Altman RD, Brandt DK, et al. Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip. Arthritis Rheum 1995;38:1535-1540.

  29. Hochberg MC, Altman RD, Brandt DK, et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. Arthritis Rheum 1995;38:1541-1546.

  30. Bellamy N, Campbell J, Wells G, et al. Intraarticular corticosteroids for osteoarthritis of the knee .Protocol.Cochrane Musculoskeletal Group. Cochrane Database of Systematic Reviews. The Cochrane Library 2002; Issue 1.

  31. Chan FK, Lanas A, Scheiman J, et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomized trial. Lancet 2010;376(9736):173-179.

  32. Singh G, Fort JG, Goldstein JL, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I study. Am J Med 2006; 119: 255–266.

  33. Crofford LJ, Lipsky PE, Brooks P, et al. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum 2000;43:4-13.

  34. Bensen WG, Fiechtner JJ, McMillen JL, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999;74:1095-1105.

  35. Hawkey CJ. COX-2 inhibitors. Lancet 1999;353:307-314.

  36. European Medicine Agency (EMEA). Onsenal. www.ema.europa.eu/ema/index.jsp

  37. European Medicine Agency (EMEA). Questions and answers on the review of etoricoxib containing medicines.www.ema.europa.eu/docs/en_GB/.../Etoricoxib_31/WC500011197.pdf

  38. Transcript of FDA Press Conference on Recommendations from the Arthritis Advisory Committee held on April 12,2007.

  39. Comité de Evaluación Clínica Terapéutica. Gaceta de la Academia Nacional de Medicina 2001;10:1-4.

  40. Bjordal JM, Ljunggren AE, Klovning A, et al. Non-steroidal antiinflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomized placebo controlled trials. BMJ 2004;329;1317.

  41. Moore RA, Derry S, McQuay HJ. Cyclo-oxigenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk. BMC Musculoskelet Disord 2007;8:73.

  42. Whelton A, Lefkowith JL, West CR, et al. Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen. Kidney Int 2006;70(8):1495-1502.

  43. Soni P, Shell B, Cawkwell G, et al. The hepatic safety and tolerability of the cyclooxygenase-2 selective NSAID celecoxib: pooled analysis of 41 randomized controlled trials. Curr Med Res Opin 2009;25(8):1841-1851.

  44. Andersohn F, Schade R, Suissa S, et al. Cyclo-oxygenase-2 selective non-steroidal antiinflammatory drugs and the risk of ischaemic stroke. Stroke 2006; 37: 1725–1730.

  45. Zhang W, Moskowitz R, Auki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II:OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008;16:137-162.

  46. Husni E, Welch V, Simon L, et al. Opioid therapy for treating osteoarthritis pain Protocol Cochrane Musculoskeletal Group. Cochrane Database of Systematic Reviews 2002; Issue 1.

  47. Caldwell JR, Rapoport RJ, Davis JC, et al. Efficacy and safety of a once-daily morphine formulation in chronic, moderate-tosevere osteoarthritis pain: results from a randomized, placebocontrolled, double-blind trial and an open-label extensiontrial. J Pain Symptom Manage 2002;23:278-291.

  48. Chappell AS, Desaiah D, Liu-Seifert H, et al. A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee. Pain Pract 2011;11(1):33-41.

  49. Chappell AS, Ossanna MJ, Liu-Seifert H, et al. Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebocontrolled trial. Pain 2009;146(3):253-260.

  50. Richy F, Bruyere O, Ethgen O, et al. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 2003;163:1514-1522.

  51. McAlindon TE, LaValley MP, Gulin JP, et al. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000; 283: 1469–1475.

  52. Roth SH. Efficacy and safety of tramadol HC1 in breakthrough musculoskeletal pain attributed to osteoarthritis. J Rheumatol 1998;25:1358-1363.

  53. Schnitzer TJ, Kamin M, Olson WH. Tramadol allows reduction of naproxen dose among patients with naproxen-responsive osteoarthritis pain. A randomized, double blind, placebocontrolled study. Arthritis Rheum1999;42:1370-1377.

  54. Towheed TE, Maxwell L, Anastassiades TP, et al. Glucosamine therapy for treating osteoartrhritis. Cochrane Database Syst Rev. 2005.

  55. Institute of Clinical Systems Improvement (ICSI). Diagnosis and Treatment of Adult Degenerative Joint Disease (DJD) osteoarthritis (OA) of the knee. Bloomington. 2007.

  56. Little CV, Parsons T, Logan S. Tratamiento a base de hierbas para la osteoartritis. En: Cochrane Library plus en español. Oxford: Update Software. 2005.

  57. Walker-Bone K. Natural remedies in the treatment of osteoarthritis. Drugs Aging 2003;20:517-526.

  58. Petrella RJ, DiSilvestro MD, Hildebrand C. Effects of hyaluronate sodium on pain and physical functioning in osteoarthritis of the knee: a randomized double-blind, placebo-controlled clinical trial. Arch Int Med 2002;162:292-298.

  59. Raynauld JP, Buckland-Wright C, Ward R, et al. Safety and efficacy of long-term intra-articular steroid injections in osteoarthritis of the knee. Arthritis Rheum 2003;48: 370-377.

  60. Mahowald M, Singh J, Dykstra D. Long term effects of intraarticular Botulinum toxin A for refractory joint pain. Neurotox Res 2006; 9: 179–188.

  61. Singh JA, Mahowald ML, Krug HE, et al. Intra-articular botulinum toxin a for painful total knee arthroplasty (tKA). Arthritis Rheum 2006; 54 (Suppl.): S541.

  62. Riesman RP, Kirwan JR, Taal E, et al. Patient education for osteoarthritis. The Cochrane Database of Systematic Reviews. The Cochrane Library 2002; Issue 1. http://gateway/ovid.com/ovidweb.cgi

  63. Felson DT, Zhang Y, Anthony JM, et al. Weigth loss reduces the risk of symptomatic knee oseoarthritis in women. Ann Intern Med 1992;116:535-539.

  64. Sharma L, Song J, Felson D, et al. The role of knee alignment in disease progression and functional decline in knee osteoarthritis. JAMA 2001; 286: 188–195.

  65. Ottawa Panel Evidence-Based Clinical Practice Guideline for Therapeutic Exercises and Manual Therapy in the Management of Osteoarthritis. Phys Therap 2005;85:907-971.

  66. Roddy E, Zhang W, Doherty M. Aerobic walking or strengthening exercise for osteoarthritis of the knee? A systematic review. Ann Rheum Dis 2005;64:544-548.

  67. Van Baar ME, Dekker J, Oostendorp RAB, et al. The effectiveness of exercise therapy in patients with osteoarthritis of the hip or knee: a randomized clinical trial. J Rheumatol 1998;25:2432-2439.

  68. Akesson K, Karsten E, Woolf AD. Improved education in musculoskeletal conditions is necessary for all doctors. Bull World Health Organ 2003; 81(9) 657-668.

  69. Hegedus B, Viharos L, Gervain M, et al. The effect of lowlevel laser in knee osteoarthritis: a double-blind, randomized, placebo-controlled trial. Photomed Laser Surg 2009;27(4):577-584.

  70. Tascioglu F, Kuzgun S, Armagan O, et al. Short-term effectiveness of ultrasound therapy in knee osteoarthritis. J Int Med Res 2010;38(4):1233-1242.

  71. Silva LE, Valim V, Pessanha AP, et al. Hydrotherapy versus conventional land-based exercise for the management of patients with osteoarthritis of the knee: a randomized clinical trial. Phys Ther 2008;88(1):12-21.

  72. Foley A, Halbert J, Hewitt T, et al. Does hydrotherapy improve strength and physical function in patients with osteoarthritis? A randomized controlled trial comparing a gym based and a hydrotherapy based strengthening programme. Ann Rheum Dis 2003;62(12):1162-1167.

  73. Astin JA. Mind-body therapies for the management of pain. Clin J Pain 2004;20(1):27-32.

  74. Dhillon M, Patel S, Bali K, et al. Platelet-rich plasma intraarticular knee injections for the treatment of degenerative cartilage lesions and osteoarthritis. Knee Surg Sports Tramatol Arthrosc 2011;19(5):863-964.

  75. Berardinelli D. Factores de crecimiento plaquetarios. Nuevo tratamiento para lesiones osteomusculares. Factores de crecimiento plaquetarios para lesiones osteomusculares y artrosis. Traumatología. http://www.danielberardinelli.com.ar/index

  76. Mahiques A. Lesiones condrales-osteocondrales. CTO-AM. http://www.cto-am.com/les_condrales.htm

  77. Filardo G, Kon E, Buda R, et al. Platelet-rich plasma intraarticular knee injections for the treatment of degenerative cartilage lesions and osteoarthritis. Knee Surg Sports Traumatol Arthrosc 2011;19(4):528-535.

  78. Tallheden T, Bengtsson C, Brantsing C, et al. Proliferation and differentiations potential of chondrocytes form osteoarthritic patients. Arhrtitis Res Ther 2005;7(3):R560-568.

  79. Brittberg M, Peterson L, Sj[ogren-Jansson E, et al. Articular cartilage engineering with autologous chondrocyte transplantation. A review of recent developments. J Bone Joint Surg Am 2003;(Suppl 3):109-115.

  80. Brittberg M, Lindahl A, Nilsson A, et al. Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. N Engl J Med 1994;331(14):889-895.

  81. Osteoarthritis of the knee. Treatment options. American Academy of Orthopaedic Surgeons (AAOS), 2004.

  82. Brouwer RW, Jakma TS, Verhagen AP, et al. Braces and orthoses for treating osteoarthritis of the knee. Cochrane Database Syst Rev 2005; 1: Cd004020.

  83. Pavia-Mota E, Larios-González MG, Briceño-Cortés. Manejo de la osteoartritis en Medicina Familiar y Ortopedia. Arch Med Fam 2005; 7(3):93-98.

  84. Ballesteros J, Palma S, Radrigán F, et al. Guía de práctica clínica en Osteoartritis. Reumatología 2005;21:6-19.

  85. Batlle-Gualda E, Esteve-Vives J, Piera MC, et al. Adaptación transcultural del cuestionario WOMAC específico para artrosis de rodilla y cadera. Rev Esp Reumatol 1999; 26: 38-45.

  86. Altman R, Alarcón G, Appelrouth D. The American College of Rheumatology criteria for the classification and reporting of OA of the hand. Arth Rheum 1990.

  87. Altman R, Asch R, Bloch D. Development of criteria for the classification and reporting of OA. Classification of OA of the knee. Arthr Rheum 1986; 29:1039-1049.

  88. Altman R. Criteria for classification of clinical osteoarthrosis. J Rheumat 1991; 18(27):10-12.




2020     |     www.medigraphic.com